News
2h
Futurism on MSNMcDonald's in Trouble as Ozempic Takes HoldFinancial services firm Redburn Atlantic put the company's stock in the bear category, coinciding with a slumpy week in which ...
In the assessment of 12-month price targets, analysts unveil insights for Reddit, presenting an average target of $148.12, a ...
While these new drugs are curbing enthusiasm for eating, they are also having a notable effect on food purchases.
2d
RetailWire on MSNMcDonald’s Stock Downgraded for the 3rd Time in a Week; Analysts Blame Rising GLP-1 Drug PopularityMcDonald’s shares have now been cut by analysts three times in as many trading days, with the latest “buy-to-sell” slap from ...
McDonald’s same-store sales are falling as the Ozempic impact reshapes eating habits–here’s what it means for the fast-food ...
The Charles Schwab Corporation (NYSE: SCHW) is one of the best wide moat stocks to buy now. On June 9, Redburn-Atlantic ...
Could GLP-1 weight loss drugs like Ozempic and changing economic winds really take a bite out of the almighty Big Mac?
“After years of outsized pricing, McDonald’s core value perception appears to be increasingly challenged,” Redburn Atlantic wrote. “Rather than prompting trade-down from full-service or fast-casual, ...
McDonald's Corp. is not alone in feeling the impact of GLP-1 weight-loss drugs, but "pricing fatigue" is a bigger problem for the fast-food giant, according to Redburn Atlantic. The equities broker ...
Here's why McDonald's is more exposed than other fast-food brands to shifts in eating habits as a result of weight-loss drugs ...
Redburn Atlantic cuts McDonald's to Sell over concerns about weight-loss drugs, pricing strategy, and traffic trends ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results